SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L.The prevalence and characteristics of fibromyalgia in the general population.Arthritis Rheum1995;38:1928.
  • 2
    Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al, for the National Arthritis Data Workgroup.Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part II.Arthritis Rheum2008;58:2635.
  • 3
    Wolfe F, Brahler E, Hinz A, Hauser W.Fibromyalgia prevalence, somatic symptom reporting, and the dimensionality of polysymptomatic distress: results from a survey of the general population.Arthritis Care Res (Hoboken)2013;65:77785.
  • 4
    McNally JD, Matheson DA, Bakowsky VS.The epidemiology of self-reported fibromyalgia in Canada.Chronic Dis Can2006;27:916.
  • 5
    Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al.The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee.Arthritis Rheum1990;33:16072.
  • 6
    Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al.The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity.Arthritis Care Res (Hoboken)2010;62:60010.
  • 7
    Richards S, Cleare A.Treating fibromyalgia.Rheumatology (Oxford)2000;39:3436.
  • 8
    Barkhuizen A.Rational and targeted pharmacologic treatment of fibromyalgia.Rheum Dis Clin North Am2002;28:26190.
  • 9
    Straube S, Derry S, Moore RA, McQuay HJ.Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports.Rheumatology (Oxford)2010;49:70615.
  • 10
    Stacey BR, Barrett JA, Whalen E, Phillips KF, Rowbotham MC.Pregabalin for postherpetic neuralgia: placebo-controlled trial of fixed and flexible dosing regimens on allodynia and time to onset of pain relief.J Pain2008;9:100617.
  • 11
    Serra E.Duloxetine and pregabalin: safe and effective for the long-term treatment of fibromyalgia?Nat Clin Pract Neurol2008;4:5945.
  • 12
    Roth T, Lankford DA, Bhadra P, Whalen E, Resnick EM.Effect of pregabalin on sleep in patients with fibromyalgia and sleep maintenance disturbance: a randomized, placebo-controlled, 2-way crossover polysomnography study.Arthritis Care Res (Hoboken)2012;64:597606.
  • 13
    Bennett RM, Friend R, Jones KD, Ward R, Han BK, Ross RL.The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties.Arthritis Res Ther2009;11:R120.
  • 14
    Okifuji A, Turk DC, Sinclair JD, Starz TW, Marcus DA.A standardized manual tender point survey I: development and determination of a threshold point for the identification of positive tender points in fibromyalgia syndrome.J Rheumatol1997;24:37783.
  • 15
    Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM.Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale.Pain2001;94:14958.
  • 16
    Bennett RM, Bushmakin AG, Cappelleri JC, Zlateva G, Sadosky AB.Minimal clinically important difference in the fibromyalgia impact questionnaire.J Rheumatol2009;36:130411.
  • 17
    Kim SM, Lee SH, Kim HR.Applying the ACR preliminary diagnostic criteria in the diagnosis and assessment of fibromyalgia.Korean J Pain2012;25:17382.
  • 18
    Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Hauser W, Katz RS, et al.Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary diagnostic criteria for fibromyalgia.J Rheumatol2011;38:111322.